Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totalling 43,100 shares, a decline of 23.6% from the August 15th total of 56,400 shares. Approximately 5.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 17,800 shares, the short-interest ratio is presently 2.4 days.

Avalo Therapeutics Stock Down 1.1 %

NASDAQ AVTX opened at $8.88 on Tuesday. Avalo Therapeutics has a 1-year low of $3.95 and a 1-year high of $52.75. The company has a 50 day moving average of $10.16 and a 200-day moving average of $10.98.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Monday, August 12th. The company reported ($14.07) EPS for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Avalo Therapeutics had a negative return on equity of 306.52% and a negative net margin of 1,639.50%. Sell-side analysts expect that Avalo Therapeutics will post -7.78 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Affinity Asset Advisors LLC bought a new stake in Avalo Therapeutics during the 1st quarter worth about $218,000. Ikarian Capital LLC acquired a new position in shares of Avalo Therapeutics during the first quarter worth approximately $1,015,000. Finally, Logos Global Management LP bought a new stake in shares of Avalo Therapeutics during the second quarter valued at approximately $6,722,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.